You are here

Article Text

Article menu
Download PDFPDF
Matters arising
Fenofibrate and losartan
  1. S S Daskalopoulou1,
  2. D P Mikhailidis1,
  3. V G Athyros2,
  4. A A Papageorgiou2,
  5. M Elisaf3
  1. 1Department of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free Hospital, Royal Free and University College Medical School, London, UK
  2. 2Atherosclerosis Unit, 2nd Propedeutic Department of Internal Medicine, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
  3. 3Department of Internal Medicine, Medical School, University of Ioannina, Greece
  1. Correspondence to:
    D P Mikhailidis
    Department of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free Hospital, Royal Free and University College Medical School, Pond street, London NW3 2QG, UK; mikhailidisaol.com

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The leader by Professor Bardin1 makes an excellent point. We could benefit from the hypouricaemic action of drugs that are not licensed for this use (for example, losartan and fenofibrate).

    Other drugs in common use may also have a uricosuric effect. For example, atorvastatin can reduce serum uric acid concentrations in patients with peripheral arterial disease or hyperlipidaemia.2–4 However, the mechanisms involved are not clear cut; we speculate that atorvastatin can increase renal …

    View Full Text